Navigation Links
KemPharm, Inc. Appoints Gordon K. "Rusty" Johnson as Chief Operating Officer and Chief Financial Officer
Date:7/15/2013

NORTH LIBERTY, Iowa, July 15, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today the appointment of Gordon K. "Rusty" Johnson as Chief Operating Officer (COO) and Chief Financial Officer (CFO). 

As COO and CFO of KemPharm, Mr. Johnson will join KemPharm's executive management team and will be responsible for enhancing the company's financial and operational initiatives and the ongoing development of KP201.  KP201 is KemPharm's lead clinical candidate in development for the treatment of acute moderate to moderately severe pain. KemPharm anticipates submitting a new drug application (NDA) for KP201 to the FDA in the second quarter of 2014.

Travis C. Mickle, Ph.D., president and CEO of KemPharm, commented, "Adding an executive with Rusty's industry knowledge and transactional expertise is a tremendous achievement for KemPharm as we continue to advance the clinical and regulatory development of KP201 and our entire pipeline.  In particular, Rusty's diverse investment banking background is exactly what KemPharm needs to propel our strategy forward as we seek to bring a new class of prescription opioid to the market; one that simultaneously deters abuse and reduces opioid-induced constipation."

Mr. Johnson's career is highlighted by over 30 years of investment banking experience including strategic financial advisory, corporate finance and sales & trading responsibilities at firms that include Piper Jaffray & Co.; WR Hambrecht + Co; Deutsche Bank; Kidder, Peabody & Co. and Credit Suisse First Boston.

Mr. Johnson has led a wide variety of public offerings, private financings and advisory assignments across multiple industries as well as for life sciences companies including, most recently, ADMA Biologics, Anthera Pharmaceuticals, Avalon Pharmaceuticals, and Clinical Data.  For New River Pharmaceuticals he led both the company's IPO and its global strategic partnering process which resulted in the partnering of New River's lead compound, NRP-104 (Vyvanse®), with Shire PLC in a $500 million transaction that ultimately led to the sale of New River to Shire for $2.6 billion.  Mr. Johnson's direct healthcare industry experience includes both pharmaceutical marketing for The Upjohn Company as well as consulting to several life sciences companies.

Rusty Johnson commented, "KP201, KemPharm's novel pain drug candidate, has the potential to truly redefine the pain therapeutic and prescription opioid market given its ability to both deter abuse and reduce OIC.  I'm honored to join KemPharm's executive team and I welcome the opportunity to leverage my experience to enable the company to capitalize on what I believe to be an industry-changing therapeutic and technology platform."

Mr. Johnson received his B.A. in Biology from the University of Missouri and his M.B.A. from Harvard Business School.

About KemPharm
KemPharm is abiopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach.  The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs in the high needs areas of pain, ADHD and other CNS diseases.  KemPharm's lead clinical candidate, KP201, is in development for the treatment of acute moderate to moderately severe pain with a new drug application (NDA) expected to be filed in the second quarter of 2014. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC). KemPharm's pipeline is also highlighted by KP511, its hydromorphone prodrug for pain, and KP415, a prodrug of methylphenidate for the treatment of ADHD.  For more information on KemPharm, please visit the company's website at www.kempharm.com.

 For KemPharm, Inc:Media / Investor Contacts:Christal Mickle

Jason Rando / Claire Sojda319-665-2575

Tiberend Strategic Advisors, Inc.info@kempharm.com

212.827.0020jrando@tiberend.comcsojda@tiberend.com 


'/>"/>
SOURCE KemPharm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Arecor Appoints Dr. Sarah Howell as Chief Operating Officer
2. Elsevier / MEDai Appoints Tom Zajac as New President
3. Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer
4. Hybrid Fuels, Inc. Appoints Industry Expert as New CEO
5. BioStorage Technologies Appoints New Member to Board of Directors
6. Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development
7. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
8. PuraMed BioScience, Inc. Appoints Sue A. Baacke, CPA, as CFO
9. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
10. MAP Pharmaceuticals Appoints W. James OShea to Board of Directors
11. Veracyte Appoints Mark Spring as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 ... ... the commercial launch of flexible packaging for their exceptionally efficient human mesenchymal ... system extends RoosterBio’s portfolio of bioprocess media products engineered to radically streamline ...
(Date:12/8/2016)... 8, 2016  Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... on developing and commercializing products to treat rare ... announced today the long-term follow-up data from its ... first-in-class Innate Defense Regulator (IDR), in the treatment ... cancer patients undergoing chemoradiation therapy (CRT).  The additional ...
(Date:12/8/2016)... 8, 2016 Savannah River Remediation LLC ... selected NewTechBio,s NT-MAX Lake & Pond Sludge ... bacteria, in conjunction with Hexa Armor/ Rhombo cover ... National Pollutant Discharge Elimination System requirements. ... steady history of elevated pH levels, above 8.5, ...
(Date:12/8/2016)... , Dec. 8, 2016   Biocept, Inc ... commercial provider of clinically actionable liquid biopsy tests ... that clinical data featuring its Target Selectorâ„¢ Circulating ... biopsy for the detection of actionable biomarkers in ... research sponsored by Sara Cannon Research Institute (SCRI), ...
Breaking Biology Technology:
(Date:11/15/2016)... Nov 15, 2016 Research and Markets has ... to 2021" report to their offering. ... ... Billion by 2021 from USD 6.21 Billion in 2016, growing at ... Growth of the bioinformatics market is driven by the growing demand ...
(Date:11/14/2016)... CLARA, Calif. , Nov. 14, 2016 ... the biometric identification market, Frost & Sullivan ... Frost & Sullivan Award for Visionary Innovation ... player in the biometric identification market by ... multi-modal verification solution for instant, seamless, and ...
(Date:6/22/2016)... Md. , June 22, 2016  The American College ... Trade Show Executive Magazine as one of the ... on May 25-27 at the Bellagio in Las ... on the highest percentage of growth in each of the ... of exhibiting companies and number of attendees. The 2015 ACMG ...
Breaking Biology News(10 mins):